Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-576,729
Closed -$49M 28
2025
Q3
$49M Sell
576,729
-769,051
-57% -$47.1M 2.76% 12
2025
Q2
$10.3M Hold
1,345,780
0.77% 24
2025
Q1
$8.41M Hold
1,345,780
0.72% 23
2024
Q4
$9.85M Hold
1,345,780
0.68% 24
2024
Q3
$15.5M Hold
1,345,780
0.81% 27
2024
Q2
$17.8M Hold
1,345,780
1.13% 25
2024
Q1
$19.2M Buy
1,345,780
+347,210
+35% +$4.48M 0.92% 28
2023
Q4
$10.7M Buy
+998,570
New +$10.2M 0.73% 27

Other funds holding ABVX

VR Adviser's ABVX Position: Q4 2025 in Review

VR Adviser sold out of Abivax (ABVX) in Q4 2025, closing a stake of 576,729 shares — an estimated $49M sold.

VR Adviser first reported a position in ABVX in Q4 2023 and held it in 8 quarters. The position peaked at $49M in Q3 2025. 247 funds tracked by Wall St. Rank hold ABVX as of Q4 2025.

  • VR Adviser reported no remaining Abivax position as of Q4 2025 after selling out during the quarter.
  • VR Adviser sold 576,729 Abivax shares in Q4 2025, an estimated $49M.
  • VR Adviser first reported a position in Abivax in Q4 2023 and held it in 8 quarters.
  • VR Adviser's Abivax position peaked at $49M in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Abivax as of Q4 2025.

Based on VR Adviser's 13F filing for Q4 2025, filed 17 Feb 2026.